About

Revealing the biological signals that shape health and disease

Signios Biosciences (Signios Bio) is the US-based arm of MedGenome, a global leader in genetic testing services, genomics research, and drug discovery solutions. 

Signios Bio is a multiomics and bioinformatics company dedicated to revealing the intricate signals within biological data. We leverage the power of multiomics—integrating data from genomics, transcriptomics, proteomics, epigenomics, metabolomics, and microbiomics—to gain a comprehensive understanding of disease biology. Our AI-powered bioinformatics platform allows us to efficiently analyze these complex datasets, uncovering hidden patterns and accelerating the development of new therapies and diagnostics.

Through the integration of cutting-edge multiomics technologies, advanced bioinformatics, and the expertise of world-class scientists, we enable researchers and clinicians with comprehensive, end-to-end solutions to improve drug discovery and development and advance precision medicine.

As part of MedGenome, we have access to real-world evidence (RWE) from global research networks across the US, Europe, Asia, Africa, Middle East, and Latin America. This access enables us to work with our partners to uncover insights that can lead to new biomarkers and drug targets, ensuring that precision medicine is inclusive and effective for all.

Our Team of Experts

Leadership

Dr. Felix Olale

President and CEO

Jennifer Rose

Chief commercial officer

Somasekar Seshagiri

CHIEF SCIENCE OFFICER

Surajit Chakrabartty

CHIEF FINANCIAL OFFICER

Angelica LaVallee

Vice President of Sales

Harsha Gowda

Sr. Principal Scientist & Director of Research & Development

Marco Corbo

Sr. Scientist & Director of Bioinformatics

Board of Directors

Dr. Amit Kakar

NOVO HOLDINGS DIRECTOR, Chairman of the Board

Mahesh Pratapneni

GROUP CEO & CO-FOUNDER, Board DIRECTOR

Tejeshwi Sharma

Managing Director, Peak XV Partners, Board Director

Michael Jelinske

Director of Investments, Leapfrog, Board Director

What’s In Our DNA Makes the Difference

We combine advanced multiomics, bioinformatics platforms, and our unrivaled expertise to deliver the high-quality results our customers expect. Having spent many years in research, our scientists understand the process of formulating hypotheses and the rigors of experimentation and data analysis.

Our team serves as an extension of our customers’ teams, collaborating on all aspects of the –omics workflow from sample prep to data analysis to get the most out of advanced sequencing technologies.

We recognize the importance of every project entrusted to us. From initial consultation through execution and completion, we provide exceptional support, managing each project with meticulous attention to detail and a commitment to achieving success for our customers.

We leverage real-world evidence (RWE) from richly diverse research programs across the US, Europe, Asia, Africa, Middle East, and Latin America. This access provides opportunities to uncover new scientific insights and support the development of therapeutics designed to benefit diverse populations, helping to address healthcare disparities.

The Signios Bio Name: Pointing the Way Forward

The name “Signios” is inspired by the word “signals.” It reflects our core mission of deciphering the complex biological signals hidden within multiomics data. Just as a radio receiver picks up signals amidst noise, Signios Bio uses advanced bioinformatics and AI to identify the critical signals within datasets of genomic, transcriptomic, proteomic, and other biological information.

These signals hold the key to understanding disease, developing new therapies, and advancing precision medicine. The name Signios Bio represents our commitment to listening to these crucial biological signals and translating them into actionable insights that can improve human health.

Our Investors

Many of the world’s leading academic and biopharmaceutical companies partner with Signios Bio to unlock deeper insights into the biology of disease and enable the future of precision medicine. Here are just a few.

Leadership

Leadership

Dr. Felix Olale

President & CEO

Linkedin

Dr. Felix Olale is an entrepreneur and physician scientist, renowned for his work in building businesses and investing in healthcare in emerging markets. Prior to his current role as CEO of Signios Biosciences, he served as the Chairman of the MedGenome Board and was Partner and the Global Co-Leader for Health Investments at LeapFrog Investments. He also serves as a Board Trustee and Chairman of the Governance Committee for PATH, a leading global health innovator and is a member of EMPEA’s Africa Council. Dr. Olale has previously been the Chairman of the Excelsior Group and Senior Advisor to the International Finance Corporation (IFC). He was also the co-founder of Strathmore Business School’s Institute for Healthcare Management, and a founding member of Safaricom’s Health Advisory Board. Dr. Olale holds a Bachelor of Arts (Hons.) in Molecular Biology from the University of Pennsylvania and Medical Degree and Doctorate from New York University’s School of Medicine.

Leadership

Leadership

Jennifer Rose

Executive Vice President & CCO

Linkedin

Jennifer Rose has over 20 years’ experience in leadership, sales, business development and commercial operations. She has worked supporting biopharmaceutical therapy research and development in various verticals for the majority of her career. She is a chemical engineer by training and has had roles supporting pharma informatics at Scientific Software (Agilent), pharmacokinetics analytics at Pharsight (Certara) and informatics and data analytics at Thomson Reuters (Clarivate Analytics). She moved into a primary focus within oncology research and development supporting bioinformatics and genomics services at PerkinElmer and biomarker assay development and clinical trial support at Clarient Diagnostics Services. At NeoGenomics Laboratories she was Senior Vice President of Pharma Services and led commercial operations including sales, scientific affairs and project management operations. Most recently she served as Regional Vice president of Business Development at Precision for Medicine. She has an MS in Chemical Engineering from the University of Connecticut and a BS in Chemical Engineering from Clemson University.

Leadership

Leadership

Somasekar Seshagiri
CHIEF SCIENCE OFFICER
Linkedin

Sekar Seshagiri is a world leader in the field of genomics and drug discovery. Prior to his current role as CSO of Signios Biosciences, he spent over 20 years at Genentech where he was a Staff Scientist and Associate Director. During his tenure at Genentech, he established a state-of-the-art genomics laboratory where he conducted research in cancer and cell signaling areas to support drug discovery and development. His research work has been at the forefront of understanding underlying genetic changes in cancer genomes through systematic identification of somatic mutations in large number of cancer types and subtypes using next generation sequencing, computational methods, and functional assays. He has authored and co-authored over 100 articles in peer-reviewed journals including Nature, Nature Genetics, Science, and Cancer Cell. He obtained his B.Sc., (Agriculture) and M.Sc., (Biotechnology) from Tamil Nadu Agricultural University, India, a M.S, (Software Engineering) from Golden Gate University, and a Ph.D. in Genetics from the University of Georgia.

Leadership

Leadership

Surajit Chakrabartty
CHIEF FINANCIAL OFFICER
Linkedin

Surajit Chakrabartty is a financial expert with over 18 years of experience across diverse sectors such as e-Commerce, Retail, Media & Advertising and Manufacturing. Process implementation and building financial enterprises are his core strengths. In his career span, Surajit has successfully managed multiple projects including ERP implementations and internal control systems design across organisations. At MedGenome & Signios Bio, he leads the finance function and is responsible for treasury management, financial forecasting, planning, and budgeting, reporting and assessing future business risks. He has successfully automated multiple processes while adhering to quality standards, rules and regulations. Surajit brings with him extensive experience and in-depth expertise of debt and other financing developed over his stellar career. Previously, he was associated with Redbus.in, Medybiz Pharma Private Limited and Rediffusion Y&R. He is also featured as one amongst India’s Most Influential CFOs (awarded by the Chartered Institute of Management Accountants). Surajit is a Chartered Accountant from ICAI.

Leadership

Leadership

Angelica LaVallee

Vice President of Sales

Linkedin

Angelica LaVallee brings over a decade of experience driving growth and innovation in the genomics and biotechnology space. With a foundation in molecular biology from UC San Diego, she has played a key role in expanding access to advanced sequencing technologies across research institutions and biopharma companies. Angelica is known for building strong relationships, developing strategic commercial initiatives, and helping teams navigate complex scientific landscapes. Her passion lies in accelerating discoveries in immuno-oncology and translational research through the thoughtful application of next-generation sequencing solutions. She has an BS in Molecular Biology from the University of California, San Diego.

Leadership

Leadership

Harsha Gowda

Sr. Principal Scientist & Director of Research & Lab Ops

Linkedin

Harsha Gowda is a well-established research scientist in biotechnology, microbiology, and proteomics. His deep knowledge of omics technologies continues to drive impactful research both for Signios Bio and their clients. At Signios Bio, Harsha is a Senior Principal Scientist and the Director of Research & Lab Operations, where he oversees research initiatives and laboratory functions across the DNA, RNA, single-cell, spatial, and sequencing labs. He received his BS in Biochemistry and Microbiology from Government Science College, Hassan, and his Master’s degree in Biotechnology from the University of Mysore. He received his PhD in cancer biology and proteomics from Johns Hopkins University and the Institute for Bioinformatics in Bangalore, India. Prior to joining Signios Bio, he held research scientist positions at Scripps, the Institute for Bioinformatics, and QIMR Berghofer Medical Research Institute.

Leadership

Leadership

Marco Corbo

Sr. Scientist & Director of Bioinformatics

Linkedin

Marco Corbo is a scientist who has been driven by an interest in the study of genomics, chromosomal evolution and epigenomics. His main projects have focused on single cell analysis, bulk/single cell multiomics and pipeline development. At Signios Bio, Marco is a Senior Scientist and the Director of Bioinformatics, where he builds tools and pipelines to analyze large amounts of omics data to aid researchers in drug development and precision medicine. He received his BS in Biology from the Università degli Studi di Palermo. He earned his MS degree in Molecular Biology and Genetics and PhD from the University of Pavia in Lombardy, Italy. His postdoctoral work was completed at UC Davis, where he focused on identification of mammalian chromosomal chromatin three-dimensional structures and their inheritance in the mammalian phylogenetic tree.

Board of Directors

Board of Directors

Dr. Amit Kakar

Managing Partner and Head of Asia Novo Holdings Chairman of the MedGenome Board

Linkedin

Board of Directors

Board of Directors

Mahesh Pratapneni

GROUP CEO & CO-FOUNDER, DIRECTOR

Linkedin

Board of Directors

Board of Directors

Tejeshwi Sharma

Managing Director, Peak XV Partners
Director
Linkedin

Board of Directors

Board of Directors

Michael Jelinske

Director of Investments Leapfrog
Director

Linkedin